secwatch.observer — SEC 8-K summary
======================================

Issuer:     ORAMED PHARMACEUTICALS INC. (ORMP)
CIK:        0001176309
Form:       8-K
Filed at:   2025-02-11T23:59:59+00:00
Accession:  0001213900-25-012244
Event type: m_and_a
Sentiment:  positive
Materiality: 0.85
Item codes: 1.01, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Oramed spins off oral insulin into OraTech JV with HTIT; $75M total investment, Nasdaq IPO planned
--------------------------------------------------------------------------------

- HTIT to invest $60M, Oramed $15M into OraTech; Oramed shareholders to receive direct stake in new Nasdaq-listed company.
- OraTech to launch Phase 3 trial of oral insulin (ORMD-0801) in US this quarter with revised protocol.
- HTIT provides supply agreement for oral insulin capsules; OraTech gets global marketing rights to Oramed's POD technology.
- OraTech also receives license for oral semaglutide (HT01B) from HTIT for markets outside greater China.
- Initial closing deadline extended to April 30, 2025; second closing by May 31, 2025 if Nasdaq listing delayed.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1176309/000121390025012244/0001213900-25-012244-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1176309/000121390025012244/ea0229914-8k_oramed.htm
  HTML page:      https://secwatch.observer/filing/0001213900-25-012244

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer